secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001711279-25-000071
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech's VYJUVEK approved in Japan for dystrophic epidermolysis bullosa
--------------------------------------------------------------------------------

- Japan's MHLW granted marketing authorization for VYJUVEK on July 24, 2025 for DEB from birth.
- First genetic medicine approved in Japan for DEB; allows home dosing and administration by patients or family.
- Based on Phase 3 data and Japanese open-label extension; all 4 patients achieved full wound closure at 6 months.
- Re-examination period is 10 years; launch expected in Japan by end of 2025.
- Previously approved in US (May 2023) and EU (April 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000071/0001711279-25-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127925000071/krys-20250725.htm
  HTML page:      https://secwatch.observer/filing/0001711279-25-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer